Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 129 posts found.

opdivo_1_1

BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer

July 25, 2019
Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …

News

Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua

May 8, 2019
Research and Development Cancer, Europe, Lorviqua, NSCLC, Pfizer, lung cancer, pharma

Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …

News
merckwindow_web

MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer

March 15, 2019
Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …

News

Roche’s Tecentriq combo scoops up European approval in first-line metastatic lung cancer

March 8, 2019
Medical Communications, Sales and Marketing Cancer, Europe, European Commission, NSCLC, Roche, lung cancer, pharma

Roche has announced the approval of the European Commission for its PD-L1 inhibitor Tecentriq (atezolizumab) when used in combination with …

News
janssen_latest_logo_on_sign_closer

J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn

November 6, 2018
Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea

Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal …

News
merckincweb2

MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer

November 1, 2018
Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …

News

Roche’s entrectinib shrinks lung tumours with two-year response duration

September 25, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, NSCLC, NSCLC< lung cancer, Roche, entrectinib

Roche was unveiled new Phase 1 and 2 data for entrectinib in the treatment of locally advanced or metastatic ROS1-positive …

News
astrazeneca_building_white

AstraZeneca chalks up European approval for Imfinzi in locally advanced, unresectable lung cancer

September 25, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MedImmune, NSCLC, lung cancer, pharma

AstraZeneca and its global biologics R&D arm MedImmune have announced the approval by the European Commission of Imfinzi (durvalumab) as …

News
merckentranceweb

Keytruda scores ground-breaking European approval in lung cancer subgroup

September 10, 2018
Sales and Marketing Cancer, EU, Europe, MSD, Merck, NSCLC, keytruda, lung cancer, pharma

Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …

News
takeda_usa_pharmaceuticals_u

Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer

July 27, 2018
Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma

Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …

News

Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori

June 28, 2018
Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma

UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …

News
astrazeneca_sign_sky

AstraZeneca’s Imfinzi becomes India’s first available immunotherapy for lung cancer

June 22, 2018
Medical Communications, Sales and Marketing AstraZeneca, Imfinzi, India, NSCLC, lung cancer, pharma

In a big step forward for India as AstraZeneca announces that its checkpoint inhibitor Imfinzi (durvalumab) has secured approval in …

News
opdivo_1_1

BMS’ Opdivo becomes first immuno-oncology agent available in China

June 18, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma

Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …

News

Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3

May 29, 2018
Manufacturing and Production, Research and Development Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the …

News

AZ’s Imfinzi hits second major milestone at Phase 3 in unresectable lung cancer

May 25, 2018
Medical Communications, Research and Development AstraZeneca, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023